Description: Alterity Therapeutics Ltd formerly known as Prana Biotechnology Ltd is active in the healthcare domain. The company is engaged in research collaboration with Takeda for the treatment of Parkinson's disease gastrointestinal neuropathology. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (PBT434) and brain cancer (PBT519), which are in pre-clinical toxicology testing.
Home Page: alteritytherapeutics.com
ATHE Technical Analysis
460 Bourke Street
Melbourne,
VIC
3000
Australia
Phone:
61 3 9349 4906
Officers
| Name | Title |
|---|---|
| Mr. Geoffrey Paul Kempler B.Sc, B.Sc. | Co-Founder & Non-Exec. Chairman |
| Dr. David A. Stamler M.D. | Chief Exec. Officer |
| Ms. Kathryn J. E. Andrews | Chief Financial Officer |
| Dr. Rudolph Emile Tanzi Ph.D. | Chief Scientific Advisor and Member of R&D Advisory Board |
| Dr. Steven D. Targum | Chief Medical Advisor |
| Dr. Robert Cherny | Head of Research |
| Mr. Phillip Allen Hains BBus(Acc), CA, MBA | Company Sec. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.5762 |
| Price-to-Sales TTM: | 2.8458 |
| IPO Date: | 2002-09-05 |
| Fiscal Year End: | June |
| Full Time Employees: | 12 |